138 results about "HEMOSTATIC POWDER" patented technology

The present invention is directed to hemostatic material containing compacted ORC powder comprising particles having an average aspect ratio from about 1 to about 18, wherein said compacted ORC powder have preferably been processed in a compaction device, such as a ball milled ORC powder. The present invention further relates to methods of making the hemostatic material and a method of treating a wound by applying the hemostatic powder onto and/or into the wound of a patient.

The invention discloses an alkyl modified chitosan/mesoporous silicon dioxide composite quick hemostatic powder and a preparation method thereof. The method comprises the following steps: 1) preparation of alkyl modified chitosan; 2) preparation of mesoporous silicon dioxide particles; and 3) preparation of composite quick hemostatic powder: dissolving the alkyl modified chitosan in an acetic acid water solution, adding polyethyleneglycol 20000 to be dissolved, adding the mesoporous silicon dioxide particles prepared in the step 2), stirring at room temperature, freeze-drying the precipitate, suspending the precipitate in dimethylsulfoxide, regulating the pH value, centrifuging, washing with deionized water, and freeze-drying to obtain the alkyl modified chitosan/mesoporous silicon dioxide composite quick hemostatic powder. The hemostatic powder disclosed by the invention can quickly stop bleeding, and is suitable for pre-hospital emergency treatment of severe bleeding wounded persons. The material has the advantages of high hemostatic speed, excellent hemostatic effect, favorable biocompatibility and histocompatibility, and no side effect.

Belonging to the field of medical equipment, the invention particularly relates to a composite hemostatic powder and a preparation method thereof. The composite hemostatic powder provided in the invention is mainly prepared by: subjecting potato starch to modification crosslinking by acetic anhydride/adipic acid-succinic anhydride, then compounding the potato starch with a hyaluronate solution, and performing drying. The preparation method employs a relatively safe modification crosslinking pattern with low-toxic residue, and the security is significantly improved. Performance of the hemostatic powder can be adjusted by pregelatinization or surface pore-forming after starch modification crosslinking and by adopting different drying and sterilization ways. Also, blending of potato starch and sodium hyaluronate makes full use of the respective advantages of the two biological materials. Compared with existing products on the market, the composite hemostatic powder provided in the invention has excellent water-absorbing capacity, adhesion, gel forming property and anti-floating property, and shows better use performance. Being able to degrade completely in vivo, the hemostatic powder has no toxic or side effect and has definite effects, and also can be further compounded with other hemostatic materials, thus having broad market prospects.

The invention belongs to the field of medical equipment, particularly relates to the field of medical biopolymer materials and provides sustained antibacterial hemostatic powder and a preparation method of the sustained antibacterial hemostatic powder. The sustained antibacterial hemostatic powder is prepared from nanometer silver, sodium carboxymethyl cellulose and alginate, and by weight, 1-3 parts of the nanometer silver, 10-20 parts of the sodium carboxymethyl cellulose and 5-10 parts of the alginate are included. According to the sustained antibacterial hemostatic powder, the nanometer silver, the sodium carboxymethyl cellulose and the alginate are used as the raw materials, and the sustained antibacterial hemostatic powder is obtained through a spray drying method; and the hemostatic powder not only has the hemostatic function, but also has the excellent antibacterial function, as degradation of the sodium carboxymethyl cellulose and the alginate after the hemostatic powder is in contact with the blood or diffusate, the contained nanometer silver is released slowly, and thus the sustained antibacterial purpose is achieved.

The invention discloses a preparation method and applications of a hemostatic material. According to the invention, by using a microsphere surface modification method, the modified starch of a modified starch microsphere shell layer is activated and coupled with chitosan amino to obtain modified starch hemostatic microspheres with the surface modified with chitosan, wherein the modified starch microspheres have good water absorption performance and can rapidly absorb moisture in blood and concentrate blood coagulation factors so as to achieve the rapid hemostatic effect, the chitosan modification can enhance the hemostatic effect, activate blood coagulation factors and form blood coagulation blocks so as to promote blood coagulation, and chitosan has a certain antibacterial activity, so that the modification of the surface with chitosan can reduce the infection risk, the addition amount of chitosan can be reduced through surface modification, and the water absorption performance and the degradation and absorption performance of the modified starch microspheres are influenced to the minimum extent; and the hemostatic powder prepared by the invention can be used for quickly stoppingbleeding of bleeding parts such as body surfaces, in-vivo tissues, organs and the like, has a certain antibacterial function, and reduces the wound infection risk.

The invention discloses porous styptic powder and a preparation method of the porous styptic powder. The preparation method comprises the following steps: rapidly cooling a solution containing a material needing to be crosslinked, carrying out ray irradiation crosslinking under low temperature, and carrying out freeze drying, thus obtaining the porous styptic powder. In the preparation method, superfine small ice crystals are obtained through rapid cooling, during the irradiation, the low temperature is guaranteed, so that the small ice crystals do not melt and are sized after the irradiation. With the adoption of the preparation method, the porous crosslinking material with small pore diameter, large porosity and large specific surface area is obtained; the ray irradiation crosslinking is adopted, in the preparation process, a crosslinking agent is not introduced, therefore, the prepared material has no biotoxicity caused by the crosslinking agent, and therefore, the preparation process is a safe, nontoxic and environmentally friendly production process; the prepared material has good prospects in the fields of hemostatic materials, drug carriers and the like.

The invention discloses starch microsphere hemostatic powder with antibacterial activity and application thereof. The preparation method of the hemostatic powder comprises the following steps of adopting soluble starch as a raw material and sodium trimetaphosphate as a crosslinking agent for preparing starch microspheres with a three-dimensional network structure by means of a reverse emulsification crosslinking approach; adding the prepared starch microspheres into a lysozyme solution to obtain the lysozyme-loaded antibacterial starch microsphere hemostatic powder. The preparation method is simple, and the prepared lysozyme-loaded antibacterial starch microsphere hemostatic powder has excellent hemostatic performance, high bacteriostatic activity and high biocompatibility and can be degraded and absorbed by the human body.

The invention relates to starch compound polysaccharide hemostatic powder and a preparation method thereof. The preparation method comprises the following steps: carrying out enzymatic denaturation on starch to obtain a porous starch solution, dissolving sodium hyaluronate in deionized water to obtain a sodium hyaluronate solution, mixing the two solutions according to a weight ratio of 50-95 parts of porous starch solution to 5-50 parts of sodium hyaluronate solution, stirring uniformly and drying, soaking the dried material in a calcium chloride solution with a certain concentration to carry out ion exchange, and grinding the material into powder after secondary drying. The material provided by the invention has efficient stypticity on wound surfaces, is biodegradable, has the functions of anti-adhesion and moisture retention, and is safe and non-toxic, simple in preparation process and low in cost.

The invention discloses a quick-acting hemostatic powder and a hemostatic spray. The quick-acting hemostatic powder comprises following components by weight; the hemostatic spray is made from following components by weight: Radix Alangii 2-5 parts, myrrh 2-8 parts, peach twig 1-3 parts, Rhizoma Corydalis 3-5 parts, Herba Rabdosiae 6-9 parts, Trogopterus dung 1-2 parts, Semen Caesalpiniae 1-3 parts, Rhizoma Curcumae Longae 3-6 parts, frankincense 4-7 parts, Crinis Carbonisatus 8-10 parts, Herba Clinopodii 8-10 parts, Cera Chinensis 1-3 parts, Terra Flava Usta 2-5 parts, Radix Pteroxygoni Giraldii 1-3 parts, Herba Agrimoniae 5-7 parts, Flos Celosiae Cristatae 2-4 parts, Folium Callicarpae Formosanae 1-3 parts, Radix Melastomae 1-3 parts, Panax notoginseng 6-8 parts, Receptaculum Nelumbinis 5-7 parts, ophicalcite 1-2 parts, pollen Typhae 1-2 parts, Herba Achillis 1-3 parts, Folium Callicarpae Macrophyllae 2-5 parts, and Radix Toddaliae Asiaticae 5-8 parts. A preferred formula is obtained by matching various herbs effective in astringency, stasis removal and blood activation and through a plurality of tests and verifications, the purpose of quick hemostasis of a wound is achieved, and processing is facilitated; both the quick-acting hemostatic powder and the hemostatic spray are made from Chinese herbs, free of chemicals, safe and reliable, and free of side effect.

The invention belongs to the field of a biomedical material, and particularly relates to a hemostatic material and a preparation method thereof. The hemostatic material is prepared from one or more of starch raw materials through acidolysis, crosslinking, negative ionization and positive ionization; carboxymethyl chitosan is connected onto anion degradable starch, so that the hemostatic effect and the water absorptivity of the prepared hemostatic material are obviously improved; in addition, the hemostatic effect is superior to that of Arista fast hemostatic powder; the obvious progress is obtained.

The invention relates to a novel absorbable hemostatic material which is easy in preparation method, low in cost and good in hemostatic effect. At present most medical hemostatic materials in China are water-soluble hemostatic gauze, and the gauze does not have anti-inflammatory and anti-bacterial effects when being used for hemostasis, and has the defects that the hemostatic speed is low, the in vivo absorption time is long, an inflammatory reaction is easy to cause and the like, and therefore people turns to hemostatic powder, however, as existing hemostatic powder is complex to prepare, high in price, not ideal in hemostatic effect and the like, the hemostatic powder is not applied as a mainstream hemostatic product. The novel absorbable hemostatic material is a guluronic acid polymer generated by an complexation reaction or crosslinking reaction of a guluronic acid monomer, polyvinyl alcohol, lavender essential oil and clove essential oil. The novel absorbable hemostatic material is good in hemostatic effect, and has the advantages that the hemostatic speed is high, the in vivo absorption time is short, broad-spectrum sterilization and anti-inflammation effects are achieved, wound healing is promoted and the like, and in addition, the novel absorbable hemostatic material is not affected by the size and position of a wound surface, and widely applicable to the fast hemostasis for war wound, trauma and other conditions.

The invention provides a method for manufacturing specific hemostatic powder, which is a necessary medicament for rescuing body injury, i.e. hemorrhage caused by current war preparation, counter strike, accidents (knife injuries and traffic accidents) in life and natural disasters (earthquakes). The specific hemostatic powder has stronger blood pressure resistance (over 200mmHg) and effective hemostasis on medium-small arterial hemorrhage, besides basic requirement of effective hemostasis and medicament absorption in human tissues. According to the characters of the traditional Chinese medicines, the prepared hemostatic powder which is not studied domestically and overseas has the functions of antiphlogosis and tissue regeneration, and common wound is naturally healed in 4 to 5 days without any scar. Because of the advantages of tissue absorption and strong hemostatic efficacy, the hemostatic powder can effectively stop bleeding in only 2 minutes on parenchymatous organic rupture (liver and spleen rupture). The hemostatic powder has obvious hemostatic effect in a specific state (patients of hypertension, liver disease, cancer and thrombocytopenia, patients in blood transfusion, and patients lacking prothrombin and the like).

The invention belongs to the technical field of medical instruments, and particularly relates to a cardiovascular clinical compression rapid hemostasis device. The cardiovascular clinical compressionrapid hemostasis device comprises a vertical column, a rotating shaft, a fixed plate, a first air cylinder, a pressing head and a controller. One end of the rotating shaft is inserted into a first cavity formed in the upper end of the vertical column, and the rotating shaft is fixedly sleeved with a rotating ring in the first cavity; the side wall of a first groove is slidably connected to a circumferentially arranged electric push rod; the driving end of the electric push rod is hinged to a first hinge rod and a second hinge rod; a second groove is formed in the lower surface of the pressinghead; a third groove is formed in the lower surface of the pressing head; a third cavity is formed in the interior of the pressing head. The cardiovascular clinical compression rapid hemostasis device, while carrying out pressing hemostasis, can realize the intermittent intelligent adjustment of the pressing force and intermittent release of the buffer to ensure the necessary blood supply demand and to avoid the occurrence of blood pressure increase, and further can improve the hemostasis effect through circulating of ice water in combination with a hemostatic powder medical solution.

The invention discloses an aperture and particle size monodisperse controllable mesoporous silicon rapid hemostatic powder and a preparation method. The preparation method includes: 1) adding cetyl trimethylammonium bromide into water, and conducting nitrogen purging under stirring; 2) under stirring, adding n-octane, methyl methacrylate, tetraethyl orthosilicate and azobis(isobutylamidine hydrochloride) into the liquid obtained in step 1) in order, using lysine or tris(hydroxymethyl)aminomethane to adjust pH, carrying out reaction, and then performing standing to obtain a milky white suspension; 3) centrifuging the milky white suspension, and conducting centrifugal washing with anhydrous ethanol; and 4) in an air atmosphere, conducting calcination to remove a mesoporous template to obtain the white aperture and particle size monodisperse controllable mesoporous silicon rapid hemostatic powder. The hemostatic powder provided by the invention can stop bleeding rapidly, and is suitable for pre-hospital emergency treatment of serious bleeding patients, and has the characteristics of very fast hemostatic rate, hemostatic effect superior to chitosan and kaolin products, good biological and tissue compatibility, and no side effect.

The invention discloses cross-linked dextran microparticles for hemostasis, and a preparation method of the cross-linked dextran microparticles. The cross-linked dextran microparticles are prepared bytaking epoxy chloropropane as a cross-linking agent and adopting a reverse suspension method; the obtained product is detected to be low in residual amount of the cross-linking agent and good in biocompatibility, thus being suitable for being used as a hemostatic material. In a preparation process of the cross-linked dextran microparticles, other organic solvents do not need to be introduced forwashing, so that the phenomenon that the residue of the organic solvents in the product affects the quality of the product is avoided. The cross-linked dextran microparticles prepared by the method have irregular edge contours, are not easily displaced after being used, and can be fixed at a hemostatic site; the cross-linked dextran microparticles prepared by the method have biodegradability, arefree from immunogenicity and cytotoxicity, and can be used as hemostatic powder in clinical practice.